[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603687":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":52,"collaborators":55,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":84,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Centre Hospitalier Universitaire Vaudois","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy volunteers",null,"Healthy volunteers with normal office blood pressure (\\\u003C140\u002F90 mmHg).\n\nLower body negative pressure during brain BOLD fMRI in 3T and 7T MRI scanner.",[13],"Diagnostic Test: Lower body negative pressure",{"label":15,"type":10,"description":16,"interventionNames":17},"Parkinson patients without orthostatic hypotension","Patients with clinically established Parkinson disease, treated by dopamine replacement therapy, and without orthostatic hypotension as shown by a Schellong test.\n\nLower body negative pressure during brain BOLD fMRI, renal contrast-enhanced ultrasound",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Parkinson patients with orthostatic hypotension","Patients with clinically established Parkinson disease, treated by dopamine replacement therapy, and having orthostatic hypotension as shown by a Schellong test.\n\nLower body negative pressure during brain BOLD fMRI, renal contrast-enhanced ultrasound",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","Lower body negative pressure","LBNP is a technique that redistributes blood from the upper body to the dependent regions of the legs, thus reducing central venous pressure and venous return and thereby activating the sympathetic nervous system (SNS). The subject is placed in a cylindrical airtight tank, which is sealed at the level of the iliac crests, and sub-atmospheric pressure is produced using a vacuum pump. It can be used to characterize the cardiovascular responses to orthostatic stress",[9,19,15],[29],{"name":30,"affiliation":31,"role":32},"Grégoire Wuerzner","CHUV","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Grégoire Wuerzner, Prof","CONTACT","+41 79 556 1973","Gregoire.Wuerzner@chuv.ch",[40],{"facility":5,"status":10,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":10},"Lausanne","Canton of Vaud","1011","Switzerland","CH",{"type":47,"coordinates":48},"Point",[49,50],6.63282,46.516,{"lat":50,"lon":49},{"type":32,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Gregoire Wuerzner; MD","Principal Investigator",[56,58],{"name":57,"class":6},"Ecole Polytechnique Fédérale de Lausanne",{"name":59,"class":6},"University Hospital, Geneva","100603687","deciphering-the-mechanisms-of-central-bp-regulation-in-patients-with-pd-associated-with-orthostatic-hypotension-100603687",false,"NCT07139756","Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension","Deciphering the Mechanisms of Central Blood Pressure Regulation in Patients With Parkinson Disease Associated With Orthostatic Hypotension: A 2-phase Observational Study With Healthy Participants and Patients With Parkinson's Disease","HYPOPARK","Phase 1:\n\nInclusion Criteria:\n\n* Signed informed consent\n* Age ≥ 18 years and \\\u003C75 years\n* Normal office blood pressure (\\\u003C140\u002F90 mmHg)\n* For women of childbearing potential: using or willing to use during the study a reliable contraception method compatible with MRI\n\nExclusion Criteria:\n\n* Schellong test showing OH (drop of Systolic BP \\>20 mmHg or Diastolic BP \\>10 mmHg)\n* Pregnant or lactating women\n* Refusal to be informed of incidental findings\n* Any medication (acute or chronic prescription) except oral contraception\n* Clinical significant abnormal blood test as assessed by the investigator\n* Chronic or acute illness\n* Concomitant participation in a clinical trial\n* Blood donation in the 60 previous days\n* Contra-indications for MRI\n* Unable to follow study procedures\n* Having a hierarchical relationship with the investigator or being family of the investigator\n\nPhase 2:\n\nInclusion Criteria:\n\n* Signed informed consent\n* Fulfilling Movement Disorder Society clinical criteria for \"clinically established PD\"\n* Age ≥18 years and \\\u003C75 years\n* PD treated by dopamine replacement therapy (DRT)\n* Willing and able to comply with the visit schedule and study procedures\n* Autonomous in daily life\n* Schellong test showing OH (drop of Systolic BP \\>20 mmHg or Diastolic BP \\>10 mmHg)(for study group with OH) or no OH (for studygroup without OH)\n* For women of childbearing potential: using or willing to use during the study a reliable contraception method compatible with MRI\n\nExclusion Criteria:\n\n* Unable to give an informed consent\n* BP \\> 180\u002F110 mmHg on 24-hour ambulatory blood pressure monitoring\n* eGFR \\\u003C 45 ml\u002Fmin\u002F1.73 ml\u002Fmin\u002Fm2 by CKD-EPI equation\n* having contra-indications for MRI\n* Pregnant or lactating women\n* Refusal to be informed of incidental findings\n* Allergy to components of contrast agent Sonovue®\n* Living in an institution\n* Dementia\n* Type 2 diabetes\n* Stroke or myocardial infarction in the past 6 months\n* Blood donation in the previous 6 months\n* Active oncology treatment\n* Having a hierarchical relationship with the investigator or being family of the investigator",true,"ALL","18 Years","75 Years",{"count":73,"type":74},130,"ESTIMATED","OBSERVATIONAL","Phase 1 objective: test the feasibility of using a 3Tesla MRI scanner instead of a 7Tesla MRI scanner to measure brainstem responses to LBNP in healthy participants.\n\nPhase 2 primary objective: compare the brainstem responses to LBNP in patients with PD associated with OH to PD patients without OH using BOLD fMRI",[78,79],"Parkinson Disease","Orthostatic Hypotension",[81,82,83],"lower body negative pressure","parkinson disease","orthostatic hypotension","NOT_YET_RECRUITING","2025-08-18",{"date":87,"type":88},"2025-08-24","ACTUAL",{"date":90,"type":74},"2025-10-01",{"date":92,"type":74},"2028-03-31",{"name":5,"class":6},1]